Dishman Carbogen Amcis Limited (DCAL.BO)
INR 274.5
(-3.18%)
INR 274.5
(-3.18%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 3.07 Billion INR | -18.59% |
| 2022 | 3.07 Billion INR | -0.69% |
| 2021 | 3.51 Billion INR | 15.52% |
| 2020 | 2.86 Billion INR | -42.31% |
| 2019 | 5.42 Billion INR | -9.56% |
| 2018 | 5.97 Billion INR | 21.58% |
| 2017 | 4.9 Billion INR | 2.46% |
| 2016 | 4.78 Billion INR | 15.51% |
| 2015 | 4.36 Billion INR | 5.1% |
| 2014 | 3.89 Billion INR | 15.73% |
| 2013 | 3.57 Billion INR | 11.84% |
| 2012 | 3.07 Billion INR | 31.16% |
| 2011 | 2.34 Billion INR | 6.25% |
| 2010 | 2.16 Billion INR | -6.58% |
| 2009 | 2.3 Billion INR | -11.84% |
| 2008 | 2.61 Billion INR | 80.83% |
| 2007 | 1.52 Billion INR | 30.53% |
| 2006 | 1.1 Billion INR | 70.54% |
| 2005 | 650.11 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 235.3 Million INR | -62.61% |
| 2023 Q4 | 626.8 Million INR | 32.91% |
| 2023 Q3 | 471.6 Million INR | -31.97% |
| 2023 FY | - INR | -18.59% |
| 2023 Q1 | 1.28 Billion INR | 156.06% |
| 2023 Q2 | 693.2 Million INR | -46.01% |
| 2022 Q2 | 874.5 Million INR | -6.93% |
| 2022 Q1 | 939.6 Million INR | 1481.82% |
| 2022 FY | - INR | -0.69% |
| 2022 Q4 | 501.4 Million INR | -58.35% |
| 2022 Q3 | 1.2 Billion INR | 37.64% |
| 2021 Q1 | 1.11 Billion INR | 74.36% |
| 2021 Q2 | 1.08 Billion INR | -2.0% |
| 2021 Q3 | 1.28 Billion INR | 18.11% |
| 2021 Q4 | 59.4 Million INR | -95.38% |
| 2021 FY | - INR | 15.52% |
| 2020 Q2 | 949.9 Million INR | 83.8% |
| 2020 Q3 | 715.6 Million INR | -24.67% |
| 2020 Q4 | 636.9 Million INR | -11.0% |
| 2020 Q1 | 516.8 Million INR | -64.76% |
| 2020 FY | - INR | -42.31% |
| 2019 Q3 | 1.34 Billion INR | -11.93% |
| 2019 Q1 | 1.27 Billion INR | -25.32% |
| 2019 FY | - INR | -9.56% |
| 2019 Q2 | 1.52 Billion INR | 19.07% |
| 2019 Q4 | 1.46 Billion INR | 9.28% |
| 2018 Q3 | 1.46 Billion INR | 1.76% |
| 2018 FY | - INR | 21.58% |
| 2018 Q4 | 1.71 Billion INR | 17.27% |
| 2018 Q2 | 1.43 Billion INR | 13.17% |
| 2018 Q1 | 1.26 Billion INR | -7.15% |
| 2017 Q2 | 1.42 Billion INR | 85.43% |
| 2017 Q3 | 1.35 Billion INR | -4.35% |
| 2017 Q4 | 1.36 Billion INR | 0.6% |
| 2017 FY | - INR | 2.46% |
| 2017 Q1 | 765.8 Million INR | -48.95% |
| 2016 FY | - INR | 15.51% |
| 2016 Q4 | 1.5 Billion INR | 31.1% |
| 2016 Q1 | 1.09 Billion INR | -1.55% |
| 2016 Q2 | 1.25 Billion INR | 14.79% |
| 2016 Q3 | 1.14 Billion INR | -8.71% |
| 2015 Q4 | 1.1 Billion INR | -1.16% |
| 2015 Q2 | 1.02 Billion INR | -6.98% |
| 2015 Q1 | 1.09 Billion INR | -20.33% |
| 2015 FY | - INR | 5.1% |
| 2015 Q3 | 1.12 Billion INR | 9.99% |
| 2014 FY | - INR | 15.73% |
| 2014 Q4 | 1.37 Billion INR | 68.47% |
| 2014 Q3 | 817.06 Million INR | -7.98% |
| 2014 Q2 | 887.96 Million INR | 11.15% |
| 2014 Q1 | 798.87 Million INR | -4.02% |
| 2013 Q2 | 988.2 Million INR | 11.58% |
| 2013 FY | - INR | 11.84% |
| 2013 Q4 | 832.32 Million INR | 25.15% |
| 2013 Q3 | 665.06 Million INR | -32.7% |
| 2013 Q1 | 885.68 Million INR | 12.93% |
| 2012 Q3 | 694.24 Million INR | 3.14% |
| 2012 Q4 | 784.29 Million INR | 12.97% |
| 2012 FY | - INR | 31.16% |
| 2012 Q2 | 673.11 Million INR | -21.94% |
| 2012 Q1 | 862.34 Million INR | -14.86% |
| 2011 Q3 | 499.87 Million INR | 0.0% |
| 2011 FY | - INR | 6.25% |
| 2011 Q4 | 1.01 Billion INR | 102.62% |
| 2010 FY | - INR | -6.58% |
| 2009 FY | - INR | -11.84% |
| 2008 FY | - INR | 80.83% |
| 2007 FY | - INR | 30.53% |
| 2006 FY | - INR | 70.54% |
| 2005 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alfavision Overseas (India) Limited | 10.12 Million INR | -30241.762% |
| Biocon Limited | 41.52 Billion INR | 92.603% |
| Blue Jet Healthcare Limited | 2.29 Billion INR | -34.005% |
| Concord Biotech Limited | 4.65 Billion INR | 34.069% |
| FERMENTA BIOTECH LIMITED | 262.68 Million INR | -1069.399% |
| GENOMIC VALLEY BIOTECH LIMITED | 147.4 Thousand INR | -2083860.869% |
| Lyka Labs Limited | 167.58 Million INR | -1732.937% |
| Panacea Biotec Limited | -200.6 Million INR | 1631.306% |
| SAMSRITA LABS LIMITED | -2.46 Million INR | 124947.081% |
| Servoteach Industries Limited | - INR | -Infinity% |
| SMS Lifesciences India Limited | 349.41 Million INR | -779.139% |
| Supriya Lifescience Limited | 1.83 Billion INR | -67.331% |
| Syngene International Limited | 10.84 Billion INR | 71.681% |
| TAKE Solutions Limited | -1.05 Billion INR | 392.319% |
| Titan Biotech Limited | 360.29 Million INR | -752.577% |
| Transgene Biotek Limited | -4.33 Million INR | 70895.114% |
| Vanta Bioscience Limited | 14.19 Million INR | -21546.114% |